Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia

Reuters12-17

Cero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings Inc. has provided a clinical update on its ongoing Phase 1 clinical trial of CER-1236, an investigational cellular immunotherapy for patients with acute myeloid leukemia (AML). The trial, known as CertainT-1, has completed the dose-limiting toxicity (DLT) observation period for the first patient in the second cohort, who received a dose level of 4e6 cells/kg, four times higher than the dose administered to the first cohort. Additionally, a second patient in the first cohort has received a fourth additional dose and remains on study. The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations. Results from the study have not yet been presented, and enrollment and dosing are ongoing with continued safety monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603551-en) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592990982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592990982","market":"us","top_or_hot":-1,"title":"Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CERo Therapeutics Holdings Inc. has provided a clinical update on its ongoing Phase 1 clinical trial of CER-1236, an investigational cellular immunotherapy for patients with acute myeloid leukemia (AML). The trial, known as CertainT-1, has completed the dose-limiting toxicity (DLT) observation period for the first patient in the second cohort, who received a dose level of 4e6 cells/kg, four times higher than the dose administered to the first cohort. Additionally, a second patient in the first cohort has received a fourth additional dose and remains on study. The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations. Results from the study have not yet been presented, and enrollment and dosing are ongoing with continued safety monitoring.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603551-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CERo Therapeutics Holdings Inc. has provided a clinical update on its ongoing Phase 1 clinical trial of CER-1236, an investigational cellular immunotherapy for patients with acute myeloid leukemia (AML). The trial, known as CertainT-1, has completed the dose-limiting toxicity (DLT) observation period for the first patient in the second cohort, who received a dose level of 4e6 cells/kg, four times higher than the dose administered to the first cohort. Additionally, a second patient in the first cohort has received a fourth additional dose and remains on study. The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations. Results from the study have not yet been presented, and enrollment and dosing are ongoing with continued safety monitoring.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603551-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CERO","symbol_name":"CERo Therapeutics Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLjbGkl:1","article_id":"2592990982","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592990982","pubTimestamp":1765976433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CERo Therapeutics Holdings Inc. has provided a clinical update on its ongoing Phase 1 clinical trial of CER-1236, an investigational cellular immunotherapy for patients with acute myeloid leukemia . The trial, known as CertainT-1, has completed the dose-limiting toxicity  observation period for the first patient in the second cohort, who received a dose level of 4e6 cells/kg, four times higher than the dose administered to the first cohort. Additionally, a second patient in the first cohort has received a fourth additional dose and remains on study. The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations. Results from the study have not yet been presented, and enrollment and dosing are ongoing with continued safety monitoring.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CERO":"CERo Therapeutics Holdings, Inc.","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Cero Therapeutics推进CER-1236治疗急性髓系白血病的1期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERO":0.9,"NDAQ":0.9},"content_text":"Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia\n    \n\n        CERo Therapeutics Holdings Inc. has provided a clinical update on its ongoing Phase 1 clinical trial of CER-1236, an investigational cellular immunotherapy for patients with acute myeloid leukemia (AML). The trial, known as CertainT-1, has completed the dose-limiting toxicity (DLT) observation period for the first patient in the second cohort, who received a dose level of 4e6 cells/kg, four times higher than the dose administered to the first cohort. Additionally, a second patient in the first cohort has received a fourth additional dose and remains on study. The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations. Results from the study have not yet been presented, and enrollment and dosing are ongoing with continued safety monitoring.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603551-en) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592990982","isCrawlerRequest":true}